Literature DB >> 32503685

Inside-Out or Outside-In: Choosing the Right Model of Hepatocellular Cancer.

Satdarshan P Monga1.   

Abstract

The incidence of hepatocellular cancer (HCC) is gradually rising. HCC occurs as a sequela to various chronic liver diseases and ensuing cirrhosis. There have been many therapies approved for unresectable HCC in the last 5 years, including immune checkpoint inhibitors, and the overall response rates have improved. However, there are many cases that do not respond, and personalized medicine is lacking, making HCC an unmet clinical need. Generation of appropriate animal models have been key to our understanding of HCC. Based on the overall concept of hepatocarcinogenesis, two major categories of animal models are discussed herein that can be useful to address specific questions. One category is described as the outside-in model of HCC and is based on the premise that it takes decades of hepatocyte injury, death, wound healing, and regeneration to eventually lead to DNA damage and mutations in a hepatocyte, which initiates tumorigenesis. Several animal models have been generated, which attempt to recapitulate this complex tissue damage and cellular interplay through genetics, diets, and toxins. The second category is the inside-out model of HCC, where clinically relevant genes can be coexpressed in a small subset of hepatocytes to yield a tumor, which matches HCC subsets in gene expression. This model has been made possible in part by the widely available molecular characterization of HCC, and in part by modalities like sleeping beauty transposon/transposase, Crispr/Cas9, and hydrodynamic tail vein injection. These two categories of HCC have distinct pros and cons, which are discussed in this Thinking Out Loud article.

Entities:  

Year:  2020        PMID: 32503685      PMCID: PMC7650009          DOI: 10.3727/105221620X15913805462476

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  50 in total

Review 1.  Burden of liver diseases in the world.

Authors:  Sumeet K Asrani; Harshad Devarbhavi; John Eaton; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

2.  Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.

Authors:  Yu Qiao; Jingxiao Wang; Eylul Karagoz; Binyong Liang; Xinhua Song; Runze Shang; Katja Evert; Meng Xu; Li Che; Matthias Evert; Diego F Calvisi; Junyan Tao; Bruce Wang; Satdarshan P Monga; Xin Chen
Journal:  Hepatology       Date:  2019-04-11       Impact factor: 17.425

3.  Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.

Authors:  Sara Torrecilla; Daniela Sia; Andrew N Harrington; Zhongyang Zhang; Laia Cabellos; Helena Cornella; Agrin Moeini; Genis Camprecios; Wei-Qiang Leow; Maria Isabel Fiel; Ke Hao; Laia Bassaganyas; Milind Mahajan; Swan N Thung; Augusto Villanueva; Sander Florman; Myron E Schwartz; Josep M Llovet
Journal:  J Hepatol       Date:  2017-08-24       Impact factor: 25.083

4.  Hepatocyte Wnts Are Dispensable During Diethylnitrosamine and Carbon Tetrachloride-Induced Injury and Hepatocellular Cancer.

Authors:  Morgan Preziosi; Minakshi Poddar; Sucha Singh; Satdarshan P Monga
Journal:  Gene Expr       Date:  2018-03-08

5.  Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease.

Authors:  Aditya Ambade; Abhishek Satishchandran; Benedek Gyongyosi; Patrick Lowe; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

6.  Cholangiocarcinomas can originate from hepatocytes in mice.

Authors:  Biao Fan; Yann Malato; Diego F Calvisi; Syed Naqvi; Nataliya Razumilava; Silvia Ribback; Gregory J Gores; Frank Dombrowski; Matthias Evert; Xin Chen; Holger Willenbring
Journal:  J Clin Invest       Date:  2012-07-17       Impact factor: 14.808

7.  Western diet-induced increase in colonic bile acids compromises epithelial barrier in nonalcoholic steatohepatitis.

Authors:  Biki Gupta; Yunshan Liu; Daniel M Chopyk; Ravi P Rai; Chirayu Desai; Pradeep Kumar; Alton B Farris; Asma Nusrat; Charles A Parkos; Frank A Anania; Reben Raeman
Journal:  FASEB J       Date:  2020-04-10       Impact factor: 5.191

8.  High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Authors:  Jean Charles Nault; Maxime Mallet; Camilla Pilati; Julien Calderaro; Paulette Bioulac-Sage; Christophe Laurent; Alexis Laurent; Daniel Cherqui; Charles Balabaud; Jessica Zucman-Rossi; Jessica Zucman Rossi
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Authors:  Kornelius Schulze; Sandrine Imbeaud; Eric Letouzé; Ludmil B Alexandrov; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Clément Meiller; Jayendra Shinde; Frederic Soysouvanh; Anna-Line Calatayud; Roser Pinyol; Laura Pelletier; Charles Balabaud; Alexis Laurent; Jean-Frederic Blanc; Vincenzo Mazzaferro; Fabien Calvo; Augusto Villanueva; Jean-Charles Nault; Paulette Bioulac-Sage; Michael R Stratton; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-03-30       Impact factor: 38.330

10.  Hepatocyte-Specific β-Catenin Deletion During Severe Liver Injury Provokes Cholangiocytes to Differentiate Into Hepatocytes.

Authors:  Jacquelyn O Russell; Wei-Yu Lu; Hirohisa Okabe; Marc Abrams; Michael Oertel; Minakshi Poddar; Sucha Singh; Stuart J Forbes; Satdarshan P Monga
Journal:  Hepatology       Date:  2019-01-04       Impact factor: 17.425

View more
  2 in total

1.  Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.

Authors:  Junyan Tao; Yekaterina Krutsenko; Akshata Moghe; Sucha Singh; Minakshi Poddar; Aaron Bell; Michael Oertel; Aatur D Singhi; David Geller; Xin Chen; Amaia Lujambio; Silvia Liu; Satdarshan P Monga
Journal:  Hepatology       Date:  2021-06-21       Impact factor: 17.298

2.  Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.

Authors:  Jinbiao Chen; Yang Zhao; Fan Zhang; Jia Li; Jade A Boland; Ngan Ching Cheng; Ken Liu; Jessamy C Tiffen; Patrick Bertolino; David G Bowen; Andreas Krueger; Leszek Lisowski; Ian E Alexander; Mathew A Vadas; Emad El-Omar; Jennifer R Gamble; Geoffrey W McCaughan
Journal:  Cell Mol Life Sci       Date:  2022-07-22       Impact factor: 9.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.